CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge
Abstract The COVID-19 pandemic presents an unprecedented challenge to global public health. Rapid development and deployment of safe and effective vaccines are imperative to control the pandemic. In the current study, we applied our adjuvanted stable prefusion SARS-CoV-2 spike (S-2P)-based vaccine,...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/97e4b89a509c4a8585861a8a1abe0884 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:97e4b89a509c4a8585861a8a1abe0884 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:97e4b89a509c4a8585861a8a1abe08842021-12-02T18:27:48ZCpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge10.1038/s41598-021-88283-82045-2322https://doaj.org/article/97e4b89a509c4a8585861a8a1abe08842021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88283-8https://doaj.org/toc/2045-2322Abstract The COVID-19 pandemic presents an unprecedented challenge to global public health. Rapid development and deployment of safe and effective vaccines are imperative to control the pandemic. In the current study, we applied our adjuvanted stable prefusion SARS-CoV-2 spike (S-2P)-based vaccine, MVC-COV1901, to hamster models to demonstrate immunogenicity and protection from virus challenge. Golden Syrian hamsters immunized intramuscularly with two injections of 1 µg or 5 µg of S-2P adjuvanted with CpG 1018 and aluminum hydroxide (alum) were challenged intranasally with SARS-CoV-2. Prior to virus challenge, the vaccine induced high levels of neutralizing antibodies with 10,000-fold higher IgG level and an average of 50-fold higher pseudovirus neutralizing titers in either dose groups than vehicle or adjuvant control groups. Six days after infection, vaccinated hamsters did not display any weight loss associated with infection and had significantly reduced lung pathology and most importantly, lung viral load levels were reduced to lower than detection limit compared to unvaccinated animals. Vaccination with either 1 μg or 5 μg of adjuvanted S-2P produced comparable immunogenicity and protection from infection. This study builds upon our previous results to support the clinical development of MVC-COV1901 as a safe, highly immunogenic, and protective COVID-19 vaccine.Chia-En LienYi-Jiun LinCharles ChenWei-Cheng LianTsun-Yung KuoJohn D. CampbellPaula TraquinaMeei-Yun LinLuke Tzu-Chi LiuYa-Shan ChuangHui-Ying KoChun-Che LiaoYen-Hui ChenJia-Tsrong JanHsiu-Hua MaCheng-Pu SunYin-Shiou LinPing-Yi WuYu-Chiuan WangMi-Hua TaoYi-Ling LinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Chia-En Lien Yi-Jiun Lin Charles Chen Wei-Cheng Lian Tsun-Yung Kuo John D. Campbell Paula Traquina Meei-Yun Lin Luke Tzu-Chi Liu Ya-Shan Chuang Hui-Ying Ko Chun-Che Liao Yen-Hui Chen Jia-Tsrong Jan Hsiu-Hua Ma Cheng-Pu Sun Yin-Shiou Lin Ping-Yi Wu Yu-Chiuan Wang Mi-Hua Tao Yi-Ling Lin CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge |
| description |
Abstract The COVID-19 pandemic presents an unprecedented challenge to global public health. Rapid development and deployment of safe and effective vaccines are imperative to control the pandemic. In the current study, we applied our adjuvanted stable prefusion SARS-CoV-2 spike (S-2P)-based vaccine, MVC-COV1901, to hamster models to demonstrate immunogenicity and protection from virus challenge. Golden Syrian hamsters immunized intramuscularly with two injections of 1 µg or 5 µg of S-2P adjuvanted with CpG 1018 and aluminum hydroxide (alum) were challenged intranasally with SARS-CoV-2. Prior to virus challenge, the vaccine induced high levels of neutralizing antibodies with 10,000-fold higher IgG level and an average of 50-fold higher pseudovirus neutralizing titers in either dose groups than vehicle or adjuvant control groups. Six days after infection, vaccinated hamsters did not display any weight loss associated with infection and had significantly reduced lung pathology and most importantly, lung viral load levels were reduced to lower than detection limit compared to unvaccinated animals. Vaccination with either 1 μg or 5 μg of adjuvanted S-2P produced comparable immunogenicity and protection from infection. This study builds upon our previous results to support the clinical development of MVC-COV1901 as a safe, highly immunogenic, and protective COVID-19 vaccine. |
| format |
article |
| author |
Chia-En Lien Yi-Jiun Lin Charles Chen Wei-Cheng Lian Tsun-Yung Kuo John D. Campbell Paula Traquina Meei-Yun Lin Luke Tzu-Chi Liu Ya-Shan Chuang Hui-Ying Ko Chun-Che Liao Yen-Hui Chen Jia-Tsrong Jan Hsiu-Hua Ma Cheng-Pu Sun Yin-Shiou Lin Ping-Yi Wu Yu-Chiuan Wang Mi-Hua Tao Yi-Ling Lin |
| author_facet |
Chia-En Lien Yi-Jiun Lin Charles Chen Wei-Cheng Lian Tsun-Yung Kuo John D. Campbell Paula Traquina Meei-Yun Lin Luke Tzu-Chi Liu Ya-Shan Chuang Hui-Ying Ko Chun-Che Liao Yen-Hui Chen Jia-Tsrong Jan Hsiu-Hua Ma Cheng-Pu Sun Yin-Shiou Lin Ping-Yi Wu Yu-Chiuan Wang Mi-Hua Tao Yi-Ling Lin |
| author_sort |
Chia-En Lien |
| title |
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge |
| title_short |
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge |
| title_full |
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge |
| title_fullStr |
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge |
| title_full_unstemmed |
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge |
| title_sort |
cpg-adjuvanted stable prefusion sars-cov-2 spike protein protected hamsters from sars-cov-2 challenge |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/97e4b89a509c4a8585861a8a1abe0884 |
| work_keys_str_mv |
AT chiaenlien cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT yijiunlin cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT charleschen cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT weichenglian cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT tsunyungkuo cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT johndcampbell cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT paulatraquina cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT meeiyunlin cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT luketzuchiliu cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT yashanchuang cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT huiyingko cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT chuncheliao cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT yenhuichen cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT jiatsrongjan cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT hsiuhuama cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT chengpusun cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT yinshioulin cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT pingyiwu cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT yuchiuanwang cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT mihuatao cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge AT yilinglin cpgadjuvantedstableprefusionsarscov2spikeproteinprotectedhamstersfromsarscov2challenge |
| _version_ |
1718378053230395392 |